BidaskClub lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a strong-buy rating to a buy rating in a report released on Tuesday morning, BidAskClub reports.

A number of other analysts also recently commented on the company. Zacks Investment Research downgraded ZIOPHARM Oncology from a buy rating to a hold rating in a report on Saturday, May 18th. HC Wainwright restated a buy rating and set a $5.50 price objective on shares of ZIOPHARM Oncology in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $5.75.

ZIOP stock opened at $5.06 on Tuesday. The company has a market cap of $842.02 million, a price-to-earnings ratio of -10.54 and a beta of 2.60. The company has a quick ratio of 8.89, a current ratio of 6.33 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $5.82 and a 200-day simple moving average of $4.42. ZIOPHARM Oncology has a 52 week low of $1.56 and a 52 week high of $7.25.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). During the same period last year, the business posted ($0.12) earnings per share. As a group, analysts expect that ZIOPHARM Oncology will post -0.33 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in ZIOP. BlackRock Inc. boosted its position in ZIOPHARM Oncology by 24.3% during the 2nd quarter. BlackRock Inc. now owns 11,753,413 shares of the biotechnology company’s stock worth $68,522,000 after purchasing an additional 2,294,498 shares during the period. Vanguard Group Inc. boosted its position in ZIOPHARM Oncology by 11.6% during the 2nd quarter. Vanguard Group Inc. now owns 11,254,728 shares of the biotechnology company’s stock worth $65,615,000 after purchasing an additional 1,167,963 shares during the period. Nuveen Asset Management LLC purchased a new stake in ZIOPHARM Oncology during the 2nd quarter worth $4,051,000. Invesco Ltd. purchased a new stake in ZIOPHARM Oncology during the 2nd quarter worth $2,602,000. Finally, SG Americas Securities LLC boosted its position in ZIOPHARM Oncology by 1,086.8% during the 2nd quarter. SG Americas Securities LLC now owns 378,669 shares of the biotechnology company’s stock worth $2,208,000 after purchasing an additional 346,763 shares during the period. 38.94% of the stock is owned by hedge funds and other institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Recommended Story: How Do Front-End Loads Impact an Investment?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.